<- Go Home
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
Market Cap
$809.7M
Volume
538.3K
Cash and Equivalents
$171.7M
EBITDA
-$141.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$24.09
52 Week Low
$7.80
Dividend
N/A
Price / Book Value
2.00
Price / Earnings
-6.64
Price / Tangible Book Value
2.00
Enterprise Value
$521.5M
Enterprise Value / EBITDA
-3.71
Operating Income
-$141.1M
Return on Equity
26.64%
Return on Assets
-18.59
Cash and Short Term Investments
$290.2M
Debt
$2.0M
Equity
$402.8M
Revenue
N/A
Unlevered FCF
-$75.2M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium